Recent research has identified several promising therapeutic strategies targeting these pathological mechanisms, including ALDH2 activators, SGLT2 inhibitors, antioxidants, and anti-inflammatory agents, which collectively offer a multifaceted approach to managing DCM in ALDH2*2 carriers. Here, ALDH2 is linked to familial dilated cardiomyopathy.